CITATION REPORT List of articles citing

Amiodarone pulmonary toxicity

DOI: 10.1016/0002-8703(83)90015-7 American Heart Journal, 1983, 106, 906-16.

Source: https://exaly.com/paper-pdf/16389612/citation-report.pdf

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
166	Amiodarone pulmonary toxicity. American Heart Journal, 1983, 106, 906-16	4.9	157
165	Amiodarone lung toxicity: a human and experimental study. 1984 , 144, 73-9		45
164	Clinical pharmacology of amiodarone. 1984 , 427, 112-26		5
163	Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. 1984 , 3, 1059-71		194
162	Clinical use and pharmacology of amiodarone. 1984 , 68, 1339-66		31
161	Antiarrhythmic therapy: clinical pharmacology update. 1984 , 24, 295-305		2
160	Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. <i>Annals of Internal Medicine</i> , 1984 , 101, 462-9	8	157
159	Pneumocystis pneumonia increases the clearance rate of inhaled 99mTc DTPA from lung to blood. <i>Chest</i> , 1985 , 88, 631-2	5.3	13
158	Antiarrhythmic drug therapy (Part 2). Benefits and hazards. <i>Chest</i> , 1985 , 88, 618-24	5.3	10
157	Amiodarone pulmonary toxicity. Assessment by bronchoalveolar lavage. <i>Chest</i> , 1985 , 88, 630-1	5.3	26
156	Generalized phospholipidosis induced by an amphiphilic cationic psychotropic drug. 1985 , 13, 335-48		25
155	Amiodarone: pharmacology and antiarrhythmic and adverse effects. 1985 , 5, 298-313		44
154	Important differences between short- and long-term hemodynamic effects of amiodarone in patients with chronic ischemic heart disease at rest and during ischemia-induced left ventricular dysfunction. 1985 , 5, 1205-11		47
153	Amiodarone pulmonary toxicity: early changes in pulmonary function tests during amiodarone rechallenge. 1985 , 6, 802-5		20
152	Amiodarone pulmonary toxicity: report of two cases associated with rapidly progressive fatal adult respiratory distress syndrome after pulmonary angiography. 1985 , 60, 601-3		64
151	Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy. 1985 , 8, 81-8		11
150	Side effects and complications of amiodarone therapy. <i>American Heart Journal</i> , 1985 , 109, 975-83	4.9	176

(1987-1985)

149	Gallium-67 lung uptake associated with amiodarone pulmonary toxicity. <i>American Heart Journal</i> , 1985 , 109, 1114-6	4.9	13
148	Electron microscopic demonstration of lysosomal inclusion bodies in lung, liver, lymph nodes, and blood leukocytes of patients with amiodarone pulmonary toxicity. 1985 , 78, 506-12		110
147	Long-term tolerance of amiodarone treatment for cardiac arrhythmias. <i>American Journal of Cardiology</i> , 1986 , 57, 1288-93	3	52
146	Amiodarone therapy and autoimmune thyroid disease. Increase in a new monoclonal antibody-defined T cell subset. 1986 , 81, 53-7		49
145	Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats. 1986, 875, 400-5		69
144	QT prolongation and the antiarrhythmic efficacy of amiodarone. 1986 , 7, 142-7		72
143	Perhexiline maleate treatment for severe angina pectoriscorrelations with pharmacokinetics. 1986 , 13, 219-29		98
142	Cobalt on the way out. 1986 , 292, 697-698		
141	Recurrent ventricular tachycardia: adverse drug reactions. 1986 , 292, 698		
140	Points: The future of BCG vaccination. 1986 , 292, 698-699		
139	Medical accountability and peer review. 1986 , 292, 698-698		
138	Amiodarone Pulmonary Toxicity: Clinical and Subclinical Features. 1986,		
137	Management of Patients with Supra ventricular Tachycardia Using Amiodarone Therapy. 1986 , 4, 516-5	521	
136	Surgical treatment of the Wolff-Parkinson-White syndrome and other supraventricular tachyarrhythmias. 1986 , 1, 117-34		22
135	Amiodarone: an effective alternative for recalcitrant supraventricular and ventricular tachycardias. 1986 , 9, 268-71		2
134	Amiodarone pulmonary toxicity: functional and ultrastructural evaluation. 1986 , 41, 100-5		55
133	Amiodarone-induced pulmonary toxicity mimicking metastatic lung disease. 1987, 63, 393-4		4
132	Atypical Pulmonary and Neurologic Complications of Amiodarone in the Same Patient. <i>Archives of Internal Medicine</i> , 1987 , 147, 1805		17

131	Amiodarone pulmonary toxicity presenting as bilateral exudative pleural effusions. <i>Chest</i> , 1987 , 92, 17	9- 8 .3	28
130	Class III drugs: amiodarone. 1987 , 8 Suppl A, 53-9		5
129	Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases. 1987 , 87, 7-13		89
128	Bronchoalveolar lavage in amiodarone pneumonitis. Cellular abnormalities and their relevance to pathogenesis. <i>Chest</i> , 1987 , 91, 214-21	5.3	64
127	A case of the blues. <i>Chest</i> , 1987 , 91, 772-3	5.3	1
126	Amiodarone-associated pulmonary fibrosis. Evidence of an immunologically mediated mechanism. <i>Chest</i> , 1987 , 92, 625-30	5.3	15
125	Drug-induced pulmonary disease. 1987 , 33, 61-120		21
124	Amiodarone induced phospholipidosis. Biochemical, morphological and functional changes in the lungs of rats chronically treated with amiodarone. 1987 , 36, 3209-14		33
123	Bronchoalveolar lavage cellular analysis and gallium lung scan in the assessment of patients with amiodarone-induced pneumonitis. 1987 , 52, 272-80		18
122	Rapid high-performance liquid chromatographic method for the determination of amiodarone and desethylamiodarone in human plasma and serum. 1987 , 415, 197-202		12
121	Amiodaronean inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. 1987 , 76, 163-72		62
120	Effects of chronic amiodarone treatment on cat myocardial phospholipid content and on in vitro phospholipid catabolism. 1987 , 78, 17-25		10
119	Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model. 1988 , 8, 591-8		37
118	Efficacy and safety of intravenous amiodarone in acute refractory arrhythmias. 1988 , 11, 481-5		16
117	Iodine in rat alveolar macrophages following amiodarone treatment: quantitative X-ray microanalysis. 1988 , 49, 339-47		5
116	In vitro inhibition of lysosomal phospholipase A1 of rat lung by amiodarone and desethylamiodarone. 1988 , 959, 316-21		52
115	Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. 1988 , 12, 781-8		59
114	Detection of amiodarone pulmonary toxicity: to screen or not to screen, that is the question!. 1988 , 12, 789-90		10

113	State of the art. The pleura. 1988 , 138, 184-234		499
112	Amiodarone-induced pneumonitis. Assessment of risk factors and possible risk reduction. <i>Chest</i> , 1988 , 93, 254-63	5.3	31
111	Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest, 1988, 93, 1067-75	5.3	209
110	Respiratory failure produced by severe procainamide intoxication in a patient with preexisting peripheral neuropathy caused by amiodarone. <i>Chest</i> , 1988 , 94, 663-5	5.3	7
109	Amiodarone pulmonary toxicity presenting as a solitary lung mass. <i>Chest</i> , 1988 , 93, 425-7	5.3	23
108	Amiodarone-induced phospholipidosis in rat alveolar macrophages. 1988 , 137, 510-8		84
107	Amiodarone in the management of cardiac arrhythmias: current concepts. 1988, 72, 321-58		17
106	Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). <i>Chest</i> , 1988 , 93, 1242-8	5.3	121
105	Gallium lung scintigraphy in amiodarone pulmonary toxicity. <i>Chest</i> , 1988 , 93, 1126-31	5.3	21
104	Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. 1989 , 80, 34-42		80
103	A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?. 1989 , 4, 400-11		4
102	A general overview of amiodarone toxicity: its prevention, detection, and management. 1989 , 31, 393-	426	91
101	Pulmonary complications of amiodarone toxicity. 1989 , 31, 447-53		14
100	The efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. 1989 , 31, 319-54		29
99	Amiodarone-induced pulmonary toxicity in the rat. <i>Lung</i> , 1989 , 167, 301-11	2.9	22
98	Pharmacology of cardiovascular drugs. 1989 , 3, 131-161		
97	Amiodarone-induced complications after cardiac operation for obstructive hypertrophic cardiomyopathy. 1989 , 48, 359-64		28
96	Serial lung function testing in patients treated with amiodarone: a prospective study. 1989 , 86, 4-10		39

95	Detection of amiodarone pulmonary toxicity. 1989 , 13, 261-2		2
94	Long-term efficacy and toxicity of high- and low-dose amiodarone regimens. 1989 , 29, 418-23		25
93	Adverse effects of amiodarone. Pathogenesis, incidence and management. 1989 , 4, 246-53		25
92	New antiarrhythmic agents in pediatrics. 1989 , 36, 1293-320		10
91	Intraoperative complications in patients receiving amiodarone: characteristics and risk factors. 1989 , 23, 757-63		12
90	The effect of amiodarone on the control of hyperthyroidism by propylthiouracil. 1990 , 33, 193-203		10
89	Pulmonary clearance of technetium 99m diethylene triamine penta-acetic acid aerosol in patients with amiodarone pneumonitis. 1990 , 17, 334-7		13
88	Pulmonary accumulation of amiodarone and N-desethylamiodarone. Relationship to the development of pulmonary toxicity. 1990 , 141, 1553-8		42
87	Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias. <i>Drug Safety</i> , 1990 , 5, 286-304	5.1	12
86	Side effects from amiodarone. <i>American Heart Journal</i> , 1991 , 121, 158-71	4.9	110
86 85	Side effects from amiodarone. <i>American Heart Journal</i> , 1991 , 121, 158-71 Natural killer cell activity in a rat model of amiodarone-induced interstitial lung disease. <i>Chest</i> , 1991 , 99, 230-4	4·9 5·3	110
	Natural killer cell activity in a rat model of amiodarone-induced interstitial lung disease. <i>Chest</i> , 1991	.,	
85	Natural killer cell activity in a rat model of amiodarone-induced interstitial lung disease. <i>Chest</i> , 1991 , 99, 230-4 Amiodarone-induced pulmonary toxicity. Immunoallergologic tests and bronchoalveolar lavage	5.3	12
8 ₅	Natural killer cell activity in a rat model of amiodarone-induced interstitial lung disease. <i>Chest</i> , 1991 , 99, 230-4 Amiodarone-induced pulmonary toxicity. Immunoallergologic tests and bronchoalveolar lavage phospholipid content. <i>Chest</i> , 1991 , 99, 363-9	5.3	12
85 84 83	Natural killer cell activity in a rat model of amiodarone-induced interstitial lung disease. <i>Chest</i> , 1991 , 99, 230-4 Amiodarone-induced pulmonary toxicity. Immunoallergologic tests and bronchoalveolar lavage phospholipid content. <i>Chest</i> , 1991 , 99, 363-9 The pharmacologic treatment of atrial fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 1991 , 5, 617-28 Amiodarone-induced pulmonary inflammation. Correlation with drug dose and lung levels of drug,	5.3	12 16 9
85 84 83 82	Natural killer cell activity in a rat model of amiodarone-induced interstitial lung disease. <i>Chest</i> , 1991 , 99, 230-4 Amiodarone-induced pulmonary toxicity. Immunoallergologic tests and bronchoalveolar lavage phospholipid content. <i>Chest</i> , 1991 , 99, 363-9 The pharmacologic treatment of atrial fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 1991 , 5, 617-28 Amiodarone-induced pulmonary inflammation. Correlation with drug dose and lung levels of drug, metabolite, and phospholipid. 1991 , 143, 1110-4	5.3	12 16 9 37
85 84 83 82 81	Natural killer cell activity in a rat model of amiodarone-induced interstitial lung disease. <i>Chest</i> , 1991 , 99, 230-4 Amiodarone-induced pulmonary toxicity. Immunoallergologic tests and bronchoalveolar lavage phospholipid content. <i>Chest</i> , 1991 , 99, 363-9 The pharmacologic treatment of atrial fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 1991 , 5, 617-28 Amiodarone-induced pulmonary inflammation. Correlation with drug dose and lung levels of drug, metabolite, and phospholipid. 1991 , 143, 1110-4 Pharmacology and pharmacokinetics of amiodarone. 1991 , 31, 1061-9 Intraoperative pulmonary edema in a patient being treated with amiodarone. <i>Anesthesia and</i>	5·3 5·3 3·9	12 16 9 37 73

77	Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. 1992 , 43, 69-110		118
76	Amiodarone and desethylamiodarone increase intrasynaptosomal free calcium through receptor mediated channel. 1992 , 345, 213-21		13
75	Amiodarone pulmonary toxicitythree unusual manifestations. 1992 , 22, 14-8		5
74	Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. 1992 , 20, 1056-62		260
73	Serial pulmonary function tests in patients treated with low-dose amiodarone. <i>American Heart Journal</i> , 1992 , 123, 1550-4	4.9	17
72	Can amiodarone pulmonary toxicity be predicted in patients undergoing implantable cardioverter defibrillator implantation?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993 , 16, 2241-9	1.6	20
71	The role of free radicals in the pathogenesis of amiodarone toxicity. <i>Journal of Cardiovascular Electrophysiology</i> , 1993 , 4, 161-77	2.7	56
70	Pharmacokinetics of amiodarone: implications for drug therapy. <i>American Journal of Cardiology</i> , 1993 , 72, 45F-50F	3	42
69	Amiodarone pulmonary toxicity in the rat is associated with increased lavage immunoglobulin and alveolar macrophages primed for increased interleukin-1 secretion. 1993 , 9, 295-9		8
68	Drug-Induced Lung Toxicity. 1993 , 12, 31-47		9
67	A complication of ambulatory blood pressure monitoring. <i>Annals of Internal Medicine</i> , 1994 , 121, 468-9	8	10
66	Management of atrial fibrillation. <i>Annals of Internal Medicine</i> , 1994 , 121, 466; author reply 467	8	1
65	Capitation and the Medicaid elderly. Annals of Internal Medicine, 1994, 121, 469-70	8	1
64	Preoperative therapy with amiodarone and the incidence of acute organ dysfunction after cardiac surgery. <i>Anesthesia and Analgesia</i> , 1997 , 85, 489-97	3.9	2
63	Preoperative Therapy with Amiodarone and the Incidence of Acute Organ Dysfunction After Cardiac Surgery. <i>Anesthesia and Analgesia</i> , 1997 , 85, 489-497	3.9	38
62	Effects of amiodarone on thyroid function. <i>Annals of Internal Medicine</i> , 1997 , 126, 63-73	8	188
61	Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. <i>Annals of Diagnostic Pathology</i> , 1997 , 1, 47-56	2.2	63
60	Dtresse respiratoire aigu[mäicamenteuse : pneumopathie et bronchiolite oblitfante		

59	Risk of complications of atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997 , 20, 2684-91	1.6	19
58	Amiodarone induced pulmonary fibrosis in infancy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 1665-7	1.6	19
57	Adverse effects of amiodarone. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 108-20	1.6	53
56	Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. <i>Archives of Internal Medicine</i> , 1998 , 158, 1669-77		49
55	Amiodarone and the thyroid. <i>Endocrine Practice</i> , 1998 , 4, 48-57	3.2	18
54	Mechanisms underlying variability in response to drug therapy: implications for amiodarone use. <i>American Journal of Cardiology</i> , 1999 , 84, 29R-36R	3	14
53	Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. <i>American Journal of Cardiology</i> , 1999 , 84, 37R-45R	3	149
52	Drugs and the pleura. <i>Chest</i> , 1999 , 116, 212-21	5.3	51
51	Amiodarone and the lung: wide variations in clinical practice. Respiratory Medicine, 2000, 94, 1130-1	4.6	7
50	Drug-induced respiratory disorders: incidence, prevention and management. <i>Drug Safety</i> , 2000 , 23, 143	-64	34
49	Reversible amiodarone-induced lung disease: HRCT findings. <i>European Radiology</i> , 2001 , 11, 1697-703	8	30
48	Estudo do efeito da amiodarona sobre o peso corplreo e sobre determinantes morfollgicos e citopatollgicos do pulmb em ratos machos e fineas das linhagens Wistar, Wistar-Kyoto e SHR. <i>Jornal De Pneumologia</i> , 2002 , 28, 309-316		2
47	[Peri-operative management of amiodarone patients.]. <i>Revista Brasileira De Anestesiologia</i> , 2004 , 54, 573-81	0.8	
46	Susceptibility to amiodarone-induced pulmonary toxicity: relationship to the uptake of amiodarone by isolated lung cells. <i>Lung</i> , 1996 , 174, 31-41	2.9	1
45	Monitoring amiodaroneß toxicities: recommendations, evidence, and clinical practice. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 110-22	6.1	43
44	Drug-induced pleural disease. <i>Clinics in Chest Medicine</i> , 2004 , 25, 141-53	5.3	83
43	Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. <i>Circulation Journal</i> , 2007 , 71, 1610-6	2.9	60
42	Part IV: Class II, Class III, and Class IV Antiarrhythmic Drugs, Comparative Efficacy of Drugs, and Effect of Drugs on Mortality IA Review of Their Pharmaco kinetics, Efficacy, and Toxicity*. <i>Journal of Cardiovascular Electrophysiology</i> , 2008 , 2, 55-87	2.7	

41	Amiodarone for refractory supraventricular tachycardias. Acta Medica Scandinavica, 1987, 221, 435-9		4
40	Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. <i>Vascular Health and Risk Management</i> , 2010 , 6, 465-72	4.4	37
39	Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. <i>Chemical Research in Toxicology</i> , 2010 , 23, 749-55	4	85
38	Amiodarone: review of pulmonary effects and toxicity. <i>Drug Safety</i> , 2010 , 33, 539-58	5.1	132
37	Effect of phenobarbitone on the pharmacokinetics and tissue levels of amiodarone in the rat. <i>Journal of Pharmacy and Pharmacology</i> , 1985 , 37, 729-31	4.8	9
36	Amiodarone-induced pulmonary toxicity. Chest Disease Reports, 2011, 1, 6	Ο	
35	Long-term efficacy of amiodarone therapy for the prevention of recurrence of paroxysmal atrial fibrillation. Analysis based on patient characteristics. <i>International Heart Journal</i> , 2011 , 52, 212-7	1.8	4
34	Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. <i>American Journal of Cardiology</i> , 2011 , 108, 705-10	3	36
33	IIII-labeled lipiodol-induced interstitial pneumonia: a series of 15 cases. <i>Chest</i> , 2011 , 139, 1463-1469	5.3	13
32	Amiodarone-induced pulmonary toxicitya fatal case report and literature review. <i>Cardiovascular Drugs and Therapy</i> , 2013 , 27, 247-54	3.9	13
31	In vivo probe-based confocal laser endomicroscopy in amiodarone-related pneumonia. <i>European Respiratory Journal</i> , 2013 , 42, 1646-58	13.6	25
30	Amiodarone and concurrent antiretroviral therapy: a case report and review of the literature. <i>Antiviral Therapy</i> , 2014 , 19, 329-39	1.6	8
29	Defining molecular initiating events in the adverse outcome pathway framework for risk assessment. <i>Chemical Research in Toxicology</i> , 2014 , 27, 2100-12	4	109
28	Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. <i>Respiratory Medicine</i> , 2014 , 108, 638-46	4.6	19
27	Obesity Is Associated With the Development of Interstitial Pneumonia Under Long-Term Administration of Amiodarone in Refractory Atrial Fibrillation Patients. <i>International Heart Journal</i> , 2016 , 57, 30-4	1.8	3
26	Autofluorescence spectro-endomicroscopy of alveoli: Comparative spectral analysis of healthy smocker volonteers and amiodarone-induced pneumonitis patients. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017 , 17, A76	3.5	
25	Drug-Induced Lung Injury. Respiratory Disease Series, 2018,	0.2	O
24	latrogenic and Toxic Injury. 1988 , 511-534		5

23	Free Radical Reactions in the Pathomechanism of Amiodarone Liver Toxicity. 1992 , 124-157		2
22	Clinical Aspects of Amiodarone Pulmonary Toxicity. <i>Clinics in Chest Medicine</i> , 1990 , 11, 119-129	5.3	32
21	Cough: Differential Diagnosis and Treatment. Clinics in Chest Medicine, 1987, 8, 177-188	5.3	36
20	Amiodarone-induced lymphocyte toxicity and mitochondrial function. <i>Journal of Cardiovascular Pharmacology</i> , 1996 , 28, 94-100	3.1	17
19	Part IV: Class II, Class III, and Class IV Antiarrhythmic Drugs, Comparative Efficacy of Drugs, and Effect of Drugs on Mortality? A Review of Their Pharmaco kinetics, Efficacy, and Toxicity. <i>Journal of Cardiovascular Electrophysiology</i> , 1988 , 2, 55-87	2.7	3
18	Therapeutic monitoring of amiodarone: pharmacokinetics and evaluation of the relationship between effect and dose/concentration. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2017 , 161, 134-143	1.7	12
17	Antiarrhythmic agents*. Medical Journal of Australia, 1984, 141, 718-723	4	1
16	Pleura and pleural disorders. 2010 , 1003-1063		
15	Cardiovascular Pharmacology. 2011 , 235-295		1
14	Amiodarone. Developments in Cardiovascular Medicine, 1988, 266-285		
14	Amiodarone. <i>Developments in Cardiovascular Medicine</i> , 1988 , 266-285 latrogene und exogen bedingte Lungenerkrankungen. <i>Handbuch Der Medizinischen Radiologie</i> , 1989 , 225-418		
	latrogene und exogen bedingte Lungenerkrankungen. <i>Handbuch Der Medizinischen Radiologie</i> ,		2
13	latrogene und exogen bedingte Lungenerkrankungen. <i>Handbuch Der Medizinischen Radiologie</i> , 1989 , 225-418 The oral antiarrhythmic drugs. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung</i>		2
13	latrogene und exogen bedingte Lungenerkrankungen. <i>Handbuch Der Medizinischen Radiologie</i> , 1989, 225-418 The oral antiarrhythmic drugs. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 1990, 35, 151-247	5-9 <u>2</u> .5	2
13 12 11	latrogene und exogen bedingte Lungenerkrankungen. Handbuch Der Medizinischen Radiologie, 1989, 225-418 The oral antiarrhythmic drugs. Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques, 1990, 35, 151-247 Drug-Induced Pulmonary Disorders. 1992, 367-373	5-9 _{2.5}	
13 12 11	latrogene und exogen bedingte Lungenerkrankungen. <i>Handbuch Der Medizinischen Radiologie</i> , 1989, 225-418 The oral antiarrhythmic drugs. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 1990, 35, 151-247 Drug-Induced Pulmonary Disorders. 1992, 367-373 A case of amiodarone-associated pulmonary toxicity. <i>Korean Journal of Internal Medicine</i> , 1995, 10, 159	5-9 _{2.5}	1
13 12 11 10	latrogene und exogen bedingte Lungenerkrankungen. <i>Handbuch Der Medizinischen Radiologie</i> , 1989, 225-418 The oral antiarrhythmic drugs. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 1990, 35, 151-247 Drug-Induced Pulmonary Disorders. 1992, 367-373 A case of amiodarone-associated pulmonary toxicity. <i>Korean Journal of Internal Medicine</i> , 1995, 10, 155 Drug-induced Pulmonary Disorders. 1999, 403-436 DLI Induced by Antiarrhythmic Drug and Antimicrobial Drug: What Are the Characteristics of DLI in		1

CITATION REPORT

5	Asymptomatic cavitary pneumonitis due to amiodarone pulmonary toxicity. <i>Texas Heart Institute Journal</i> , 1985 , 12, 371-5	0.8	1
4	Amiodarone for refractory cardiac arrhythmias: 10-year study. <i>Cmaj</i> , 1986 , 134, 495-501	3.5	1
3	Segmental pulmonary consolidation due to amiodarone. <i>Cmaj</i> , 1986 , 134, 611-3	3.5	3
2	Amiodarone-induced lung toxicity. In vitro evidence for the direct toxicity of the drug. <i>American Journal of Pathology</i> , 1985 , 120, 344-50	5.8	50
1	Amiodarone-Induced Lung Toxicity: A Case Initially Not Correctly Framed. 2023,		0